Unknown

Dataset Information

0

Glutamine Antagonist JHU-083 Normalizes Aberrant Hippocampal Glutaminase Activity and Improves Cognition in APOE4 Mice.


ABSTRACT: BACKGROUND:Given the emergent aging population, the identification of effective treatments for Alzheimer's disease (AD) is critical. OBJECTIVE:We investigated the therapeutic efficacy of JHU-083, a brain-penetrable glutamine antagonist, in treating AD using the humanized APOE4 knock-in mouse model. METHODS:Cell culture studies were performed using BV2 cells and primary microglia isolated from hippocampi of adult APOE4 knock-in mice to evaluate the effect of JHU-083 treatment on LPS-induced glutaminase (GLS) activity and inflammatory markers. Six-month-old APOE4 knock-in mice were administered JHU-083 or vehicle via oral gavage 3x/week for 4-5 months and cognitive performance was assessed using the Barnes maze. Target engagement in the brain was confirmed using a radiolabeled GLS enzymatic activity assay, and electrophysiology, gastrointestinal histology, blood chemistry, and CBC analyses were conducted to evaluate the tolerability of JHU-083. RESULTS:JHU-083 inhibited the LPS-mediated increases in GLS activity, nitic oxide release, and pro-inflammatory cytokine production in cultured BV2 cells and primary microglia isolated from APOE4 knock-in AD mice. Chronic treatment with JHU-083 in APOE4 mice improved hippocampal-dependent Barnes maze performance. Consistent with the cell culture findings,postmortem analyses of APOE4 mice showed increased GLS activity in hippocampal CD11b+ enriched cells versus age-matched controls, which was completely normalized by JHU-083 treatment. JHU-083 was well-tolerated, showing no weight loss effect or overt behavioral changes. Peripheral nerve function, gastrointestinal histopathology, and CBC/clinical chemistry parameters were all unaffected by chronic JHU-083 treatment. CONCLUSION:These results suggest that the attenuation of upregulated hippocampal glutaminase by JHU-083 represents a new therapeutic strategy for AD.

SUBMITTER: Hollinger KR 

PROVIDER: S-EPMC7678030 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Glutamine Antagonist JHU-083 Normalizes Aberrant Hippocampal Glutaminase Activity and Improves Cognition in APOE4 Mice.

Hollinger Kristen R KR   Zhu Xiaolei X   Khoury Elizabeth S ES   Thomas Ajit G AG   Liaw Kevin K   Tallon Carolyn C   Wu Ying Y   Prchalova Eva E   Kamiya Atsushi A   Rojas Camilo C   Kannan Sujatha S   Slusher Barbara S BS  

Journal of Alzheimer's disease : JAD 20200101 1


<h4>Background</h4>Given the emergent aging population, the identification of effective treatments for Alzheimer's disease (AD) is critical.<h4>Objective</h4>We investigated the therapeutic efficacy of JHU-083, a brain-penetrable glutamine antagonist, in treating AD using the humanized APOE4 knock-in mouse model.<h4>Methods</h4>Cell culture studies were performed using BV2 cells and primary microglia isolated from hippocampi of adult APOE4 knock-in mice to evaluate the effect of JHU-083 treatmen  ...[more]

Similar Datasets

| S-EPMC7920530 | biostudies-literature
| S-EPMC6657308 | biostudies-literature
| S-EPMC6372721 | biostudies-literature
| S-EPMC6279743 | biostudies-literature
| S-EPMC10452834 | biostudies-literature
| S-EPMC6070111 | biostudies-literature
| S-EPMC5589418 | biostudies-literature
| S-EPMC10291850 | biostudies-literature
| S-EPMC5796690 | biostudies-literature
2023-02-22 | GSE214273 | GEO